803P Patient-reported outcomes in patients with resected, stage III BRAF V600+ melanoma treated with adjuvant dabrafenib + trametinib: COMBI-APlus study
Jean‐Jacques Grob(Aix-Marseille Université), Victoria Atkinson(Greenslopes Private Hospital), Alexander M. Menzies(The University of Sydney), Hiya Banerjee(Tris Pharma (United States)), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), B. Ryll, M.R. Lau(Novartis (Switzerland)), Helen Gogas(National and Kapodistrian University of Athens), Caroline Robert(Institut Gustave Roussy), Avinash Gupta(ITM University), M. Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cited by 2
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k